Scarica l'app Stockscreener
3.54
2.75%
-0.10
Dopo l'orario di chiusura:
3.55
0.010
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - simplywall.st
RECURSION PHARMACEUTICALS Director Sells 170,000 Shares - TradingView
Rafferty Asset Management LLC Purchases 394,022 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Uncovering a Potential 84.97% Upside in Biotech - DirectorsTalk Interviews
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead (NASDAQ:RXRX) - Seeking Alpha
RXRX: Integrated platform, strong partnerships, and disciplined pipeline drive innovation and growth - TradingView
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Vanguard Group Inc. Purchases 3,708,975 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals Stock Hits Day Low of $3.33 Amid Price Pressure - Markets Mojo
Assessing Recursion Pharmaceuticals (RXRX) After A 51% One Year Share Price Decline - Sahm
Recursion’s REC-4881 Milestone And Cash Runway Shift Risk Reward Profile - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals : 2025 Shareholder Letter and Business Overview - marketscreener.com
Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis - Sahm
Recursion Pharmaceuticals Opens with 11.05% Gain Despite Recent Declines - Markets Mojo
Recursion Pharmaceuticals (RXRX) hits clinical milestones as 2025 revenue grows to $74.7M - MSN
Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M - Yahoo Finance
Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Maintains Neutral on Recursion Pharmaceuticals (RXRX) Feb 25, 2026 - Meyka
Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue - simplywall.st
Recursion Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-02-25 - Seeking Alpha
Recursion Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Recursion Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate - timothysykes.com
Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 EPS and Revenue Estimates - MEXC
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic (NASDAQ:RXRX) - Seeking Alpha
BofA cuts Recursion Pharmaceuticals stock price target on launch timing - Investing.com
Recursion (RXRX) Q4 2025 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Recursion stock jumps after solid Q4 beat (RXRX:NASDAQ) - Seeking Alpha
Recursion’s AI-Enabled Drug Discovery Wins Spotlight at NVIDIA’s Conference - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results - MarketBeat
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - The Globe and Mail
What's Behind The Jump In Recursion Pharmaceuticals Stock? - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Recursion Pharmaceuticals Receives Spotlight with AI-driven Innovations at NVIDIA’s GTC - StocksToTrade
Recursion Q4 2025 slides: AI platform delivers first clinical proof-of-concept - Investing.com UK
Earnings call transcript: Recursion Pharmaceuticals beats Q4 2025 forecasts - Investing.com
This $4 Stock Could Be Your Ticket to Millionaire Status - AOL.com
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c) - TipRanks
Recursion Pharmaceuticals earnings beat by $0.09, revenue topped estimates - Investing.com UK
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion Highlights AI Validation, Extends Cash Runway to 2028 - TipRanks
Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises - marketscreener.com
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - markets.businessinsider.com
Recursion Pharmaceuticals: Fourth Quarter Financial Highlights - Bitget
Earnings Flash (RXRX)Recursion Pharmaceuticals Posts Q4 Loss $0.21 a Share, vs. FactSet Est of $0.21 Loss - marketscreener.com
Recursion Reports Clinical Milestones and Financial Results for Q4 2025, Including AI-Driven Insights Leading to Patient Outcomes - Quiver Quantitative
RECURSION PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
RXRX: AI-driven platform validated clinically, strong partner milestones, and cash runway into 2028 - TradingView
AI drug maker Recursion (NASDAQ: RXRX) grows revenue, narrows Q4 loss - Stock Titan
ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025 - Benzinga
Recursion Pharmaceuticals's Earnings Outlook - Benzinga
Recursion Pharmaceuticals in focus: Can earnings validate AI drug model? By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals in focus: Can earnings validate AI drug model? - Investing.com
Recursion Pharmaceuticals, Inc. $RXRX Position Trimmed by Vestmark Advisory Solutions Inc. - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Evaluating a Potential 105% Upside in the Biotech Sector - DirectorsTalk Interviews
Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Report Pre - GuruFocus
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):